SETD2 and prostate carcinoma: SETD2 promotes the degradation of EZH2 by methylating the EZH2 K735 site, preventing transformation of cells to a high H3K27me3 chromatin state, thereby inhibiting the molecular mechanism of prostate cancer metastasis.